Moody Aldrich Partners LLC purchased a new position in shares of Masimo Co. (NASDAQ:MASI) during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 29,893 shares of the medical equipment provider’s stock, valued at approximately $2,919,000. Moody Aldrich Partners LLC owned about 0.06% of Masimo at the end of the most recent quarter.
Other large investors have also recently bought and sold shares of the company. Mount Yale Investment Advisors LLC acquired a new position in shares of Masimo in the 1st quarter worth approximately $101,000. Northwestern Mutual Wealth Management Co. purchased a new stake in Masimo during the 2nd quarter worth approximately $109,000. Cerebellum GP LLC purchased a new stake in Masimo during the 2nd quarter worth approximately $173,000. US Bancorp DE increased its stake in Masimo by 36.9% during the 2nd quarter. US Bancorp DE now owns 1,980 shares of the medical equipment provider’s stock worth $193,000 after buying an additional 534 shares during the period. Finally, Matisse Capital purchased a new stake in Masimo during the 2nd quarter worth approximately $202,000. Institutional investors own 83.25% of the company’s stock.
MASI has been the topic of several recent research reports. BidaskClub downgraded shares of Masimo from a “strong-buy” rating to a “buy” rating in a research report on Saturday, June 30th. ValuEngine raised shares of Masimo from a “hold” rating to a “buy” rating in a research report on Monday, July 2nd. Zacks Investment Research raised shares of Masimo from a “hold” rating to a “buy” rating and set a $110.00 price objective on the stock in a research report on Tuesday, July 3rd. Stifel Nicolaus increased their price objective on shares of Masimo from $108.00 to $112.00 and gave the company a “buy” rating in a research report on Thursday, August 2nd. Finally, Needham & Company LLC initiated coverage on shares of Masimo in a research report on Friday, September 14th. They issued a “buy” rating on the stock. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $109.20.
In other news, Director Sanford Fitch sold 2,000 shares of Masimo stock in a transaction dated Wednesday, August 1st. The shares were sold at an average price of $101.00, for a total transaction of $202,000.00. Following the completion of the sale, the director now directly owns 57,832 shares in the company, valued at $5,841,032. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Steven Barker sold 10,000 shares of Masimo stock in a transaction dated Thursday, August 9th. The stock was sold at an average price of $110.00, for a total transaction of $1,100,000.00. Following the sale, the director now owns 74,832 shares of the company’s stock, valued at $8,231,520. The disclosure for this sale can be found here. Insiders sold a total of 765,380 shares of company stock valued at $90,720,456 in the last quarter. Insiders own 12.60% of the company’s stock.
NASDAQ:MASI traded up $2.51 during trading hours on Friday, reaching $117.13. 379,288 shares of the company’s stock were exchanged, compared to its average volume of 524,720. Masimo Co. has a 1-year low of $80.69 and a 1-year high of $126.89. The stock has a market cap of $6.45 billion, a P/E ratio of 47.81, a P/E/G ratio of 2.91 and a beta of 1.00.
Masimo (NASDAQ:MASI) last released its earnings results on Wednesday, August 1st. The medical equipment provider reported $0.73 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.71 by $0.02. The company had revenue of $211.62 million during the quarter, compared to analysts’ expectations of $207.85 million. Masimo had a net margin of 15.30% and a return on equity of 21.49%. The business’s revenue was up 10.0% on a year-over-year basis. During the same quarter last year, the business earned $0.83 EPS. Analysts anticipate that Masimo Co. will post 2.9 earnings per share for the current fiscal year.
Masimo Company Profile
Masimo Corporation, a medical technology company, develops, manufactures, and markets noninvasive monitoring technologies worldwide. The company offers Masimo Signal Extraction Technology (SET) pulse oximetry with measure-through-motion and low-perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry.
Featured Article: How is an ETF different from a mutual fund?
Receive News & Ratings for Masimo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Masimo and related companies with MarketBeat.com's FREE daily email newsletter.